Defining Frail Patients in Multiple Myeloma
Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.
EP: 1.Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 2.Available Induction Regimen Options for Patients with Transplant-Eligible NDMM
EP: 3.Recap: Recent Research in Multiple Myeloma
EP: 4.Evaluating MRD-Guided Therapy in Patients with NDMM
EP: 5.Assessing Response and Duration of Treatment in Transplant-Eligible NDMM
EP: 6.Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma
EP: 7.Selecting Frontline Treatment Regimens for Transplant-Ineligible MM
EP: 8.Data Updates in Transplant Ineligible NDMM
EP: 9.Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM
Now Viewing
EP: 10.Defining Frail Patients in Multiple Myeloma
EP: 11.Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 12.Bispecifics in Development for the Treatment of R/R MM
EP: 13.Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
